| Shivangi Vachhani, MD | |
|
3700 Joseph Siewick Dr Ste 408a, Fairfax, VA 22033-1745 | |
| (877) 511-4625 | |
| (703) 204-9006 |
| Full Name | Shivangi Vachhani |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 3700 Joseph Siewick Dr Ste 408a, Fairfax, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003105875 | NPI | - | NPPES |
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
David Blumenthal, the national coordinator for health information technology for the U.S. Department of Health and Human Services, "defended the administration's new plans against critics who say the watered-down rules miss an opportunity to lower costs and improve patient care," The Salt Lake Tribune reports.
The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.
New data presented at the American Thoracic Society's 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.
Ministers have accepted the advice of the Committee on Safety of Medicines (CSM) that simvastatin 10mg (Zocor Heart Pro) could be safely sold through pharmacies to reduce the risk of a first major coronary event in people likely to be at a moderate risk of coronary heart disease (CHD).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shivangi Vachhani, MD 211 Gibson St Nw Ste 220, Leesburg, VA 20176-2115 Ph: (877) 511-4625 | Shivangi Vachhani, MD 3700 Joseph Siewick Dr Ste 408a, Fairfax, VA 22033-1745 Ph: (877) 511-4625 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.
David Blumenthal, the national coordinator for health information technology for the U.S. Department of Health and Human Services, "defended the administration's new plans against critics who say the watered-down rules miss an opportunity to lower costs and improve patient care," The Salt Lake Tribune reports.
The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.
New data presented at the American Thoracic Society's 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.
Ministers have accepted the advice of the Committee on Safety of Medicines (CSM) that simvastatin 10mg (Zocor Heart Pro) could be safely sold through pharmacies to reduce the risk of a first major coronary event in people likely to be at a moderate risk of coronary heart disease (CHD).
› Verified 5 days ago
Dr. Raymund S Cuevo, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8081 Innovation Park Dr, Fairfax, VA 22031 Phone: 571-472-4724 Fax: 571-472-0241 | |
Dr. Michael Maitland, M.D., PH.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8081 Innovation Park Dr, Fairfax, VA 22031 Phone: 571-472-4724 Fax: 571-472-1601 | |
Dr. Paul G. Rochmis, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3027 Javier Rd, Suite 2, Fairfax, VA 22031 Phone: 703-573-2220 Fax: 703-573-7767 | |
Aswani Kumar Suthrave, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3600 Joseph Siewick Dr, Fairfax, VA 22033 Phone: 703-391-3600 | |
Nader H Balba, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3028 Javier Rd Ste 500, Fairfax, VA 22031 Phone: 703-698-8960 Fax: 571-494-5794 | |
Rona Harthill Earle, Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3020 Hamaker Ct Ste B102, Fairfax, VA 22031 Phone: 703-573-4072 Fax: 703-572-2153 |